GH Research Reports 73% Remission in TRD with GH001; Global Pivotal Trial Set for 2026

Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months...

July 25, 2025 | Friday | News
Clearside Biomedical Secures Health Canada Approval for XIPERE® in Treating Uveitic Macular Oedema

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

July 25, 2025 | Friday | News
4TEEN4 Pharmaceuticals Doses First Patient in PROCARD1 Trial for Groundbreaking Shock Therapy

4TEEN4 Pharmaceuticals GmbH  announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal anti...

July 25, 2025 | Friday | News
Sygnature Discovery Doubles High-Throughput Chemistry Capacity with £1M Investment

  Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancemen...

July 24, 2025 | Thursday | News
HMNC and Spruce Launch Phase 2 TAMARIND Trial to Explore Precision Treatment for Depression

HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: S...

July 23, 2025 | Wednesday | News
Corteria Pharmaceuticals Advances Dual CRF2 Agonist Pipeline for Heart Failure and Obesity

Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, ...

July 22, 2025 | Tuesday | News
SpringWorks Wins EU Nod for EZMEKLY® in NF1-Related Tumours

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced  that the European Commission (EC) granted conditi...

July 21, 2025 | Monday | News
Imugene Reports 75% Overall Response Rate in U.S.–Australia Phase 1b Trial of Off-the-Shelf CAR T Therapy for Relapsed DLBCL

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall R...

July 15, 2025 | Tuesday | News
Ultragenyx Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A

Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its Biologics L...

July 14, 2025 | Monday | News
Trethera’s TRE-515 Receives FDA Fast Track Designation for Advanced Prostate Cancer Treatment

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...

July 11, 2025 | Friday | News
Angelini Ventures Co-Leads CHF79M Series B in NUCLIDIUM to Advance Copper-Based Radiotheranostics

  Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech a...

July 11, 2025 | Friday | News
Ascentage Pharma Secures China’s First Approval for Bcl-2 Inhibitor in CLL/SLL with Lisaftoclax

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it...

July 11, 2025 | Friday | News
Purespring Therapeutics Receives FDA Clearance to Initiate Clinical Trials for IgA Nephropathy Gene Therapy

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, announces that the U.S. Food and Drug A...

July 10, 2025 | Thursday | News
Longeveron Receives FDA Clearance to Begin Phase 2 Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy

 Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

July 09, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close